Index

Page numbers in italics denote figures, those in bold denote tables.

A
abiraterone acetate, prostate cancer 339
ABVD regimen 136, 396
AC220 436
acemannoblastic leukaemia (AML) 772, 771
diagnosis 615–16, 676
actin 601
actinocrotitcorticotropic hormone see ACTH
ACTH-secreting tumours
acromegaly
acral lentiginous melanoma
Ackerman tumour
acinic cell carcinoma
acetaminophen 436
AC220 436
ABVD regimen 136, 396
abiraterone acetate, prostate cancer
A
adenosquamous carcinoma
adenoid cystic carcinoma
adenocarcinoma
acute promyelocytic leukaemia (APL) 436–7
tumour markers 432
acute promyelocytic leukaemia (APL) 436–7
adenocarcinoma
cervix 455
oesophagus 282, 291–5
clinical trials 295
controversies 295
treatment 292–4
treatment principles 291, 291–2
pancreas 272
salivary gland 575
vulva 496
adenoid cystic carcinoma 574
sinonasal 588
adenoma 92
adrenal 642
pituitary 611, 614, 616
treatment 623
salivary gland 574
adenosquamous carcinoma
mouth 527
pancreas 272
adjustment reactions 166
adjuvant therapy 102–3, 126, 127
see also specific therapies
adrenal anatomy 642
adrenal disease
functional
cortex 642, 643
medulla 647–50, 647–50
non-functional 650–1
adrenal insufficiency 150
adrenal tumours 641–55
aetiology and physiology
clinical trials 655
controversies 654
diagnostic work-up 644–6, 644–5, 646
presentation and natural history 644
prognostic factors 646
research priorities 655
staging 646, 646
transfusion therapy 153
anal cancer 327–32
clinical trials 331–2, 331–2
diagnostic work-up 328–9
HIV-related 798, 800, 801, 806–7

Index

central nervous system tumours (continued)
radiotherapy 709, 715–16
steroids 709
surgery 709, 715
systemic therapy 709, 716–17
capacitance 138
cervical cancer 449–66
anatomy and physiology 450, 450
Bethesda classification 456
clinical trials 465
diagnosis 138, 457–8, 458
epidemiology 136
follow-up 464
HIV-related 464–5, 798, 800, 801, 805
HPV-related 451, 452–3, 454, 455, 456–7, 798, 800, 801
imaging 79, 80
incidence and aetiology 451
mortality 452
pathology 454–5
pregnant women 136, 465
presentation and natural history 456–7, 457
prevention 452–3
prognostic factors 460
risk factors 8
screening 451–2, 452
staging 136, 458, 459
treatment 461–4
principles 460–1
radiotherapy 463, 463
surgery 461–2
systemic therapy and chemoradiation 464
cetuximab 125
colorectal cancer 125, 323
oral cancers 538
C-factor 38
Charlson Score 100
chemoradiotherapy (CRT) 108, 116–17
anal cancer 330–1
cervical cancer 464
colorectal cancer 314
oesophageal cancer 290–1
oral cancers 537
choreceptor trigger zone 176
chemotherapy 124–33
CNS tumours 709
cytotoxic 124
toxicities 124–5
immune therapy 126
molecularly targeted see targeted therapy
older patients 140, 142, 142
oral cancers 537
pain induced by 163, 172
pregnancy 135
see also systemic therapy; and individual drugs and cancers
Child-Pugh classification 251, 251
children see paediatric tumours
chlorambucil
CLL 447
non-Hodgkin lymphoma 411
clonogenic cells 176, 178
CHOP regimen 396
cholangiocarcinoma see biliary cancers
CHOP regimen 128, 412, 739
chromogranin 89, 601, 659
chronic lymphatic leukaemia (CLL) 444–7
diagnostic work-up 445, 445
differential diagnosis 445
epidemiology 444
pathogenesis 444
presentation 444–5
prognostic factors 445, 445
staging 445, 445
treatment 446–7, 446, 447
chronic myeloblastic leukaemia (CML) 772
chronic myeloid leukaemia (CML) 441–4
diagnostic work-up 442
pathogenesis 441–2
presentation 442, 442
research priorities 444
risk calculation 443
treatment 442–4
-allogeneic stem cell transplantation 444
tyrosine kinase inhibitors 442–4, 443
clsiplatin 110, 116
adrenal tumours 654
anal cancer 330
biliary cancers 268
bladder cancer 350
bone tumours 750, 751
cervical cancer 464
CUP (cancer of unknown primary) 795
germ cell tumours 489
head and neck cancers 509, 606
lung cancer 214, 218
nasopharyngeal cancer 520
neuroendocrine tumours 669
oesophageal cancer 289
oral cancers 538
ovarian cancer 488
patient co-morbidities 132
penile cancer 389
testicular cancer 381
uterine cancer 475
citalopram 156, 166
CK5/6 89, 601
Ck7/20 89, 601
C-Kit 579
clarithromycin 138
drug interactions 143
classification of cancers 23
clinical 35, 36–7, 36
see also staging
clinical decision-making 43
support systems 60, 60
clinical endpoints 40
clinical informatics 57–8
clinical practice guidelines (CPGs) 12–22, 14
components of 16–22, 17–18
content 12–13
CPGs development group 16
development 19–22, 20, 21
external review 21–2
levels of evidence 13–16, 14, 15
protocol development 16–17
quality appraisal 20, 20
recommendations 21, 21
topic selection 16
updating 22
clinical research informatics 55–6
clinical standards 13, 14
clinical target volume 118–19
Clinical Trial Processor 59
clinical trials 5
adrenal tumours 655
anal cancer 331–2, 331–2
biliary cancers 269
bladder cancer 351–2
bone tumours 752
breast cancer 239–40
Cervical cancer 465
CNS tumours 723, 724
colorectal cancer 325
disclosure of data 58
gastric cancer 305–6
head and neck cancers, unknown primary 607
Hodgkin lymphoma 398
interim analysis 42
laryngeal cancer 556–7
liver cancer 260–1
lung cancer 219
myeloma 425
nasopharyngeal cancer 521–2
neuroendocrine tumours 671, 672
oral cancers 540
oropharyngeal cancer 569
ovarian cancer 490
pancreatic cancer 278
pituitary tumours 624
prostate cancer 341
RCTs see randomized controlled trials
renal cell carcinoma 366
salivary gland tumours 585
sample size estimation 42
skin cancer
melanoma 703–4
NMSC 687
soft tissue tumours 766
targeted therapy 476
testicular cancer 382–3
thyroid cancers 639
uveal melanoma 743
vs. real world learning 60–1, 61, 61
vulval cancer 501
CLL see chronic lymphatic leukaemia
CML see chronic lymphatic leukaemia
Clonorchis sinensis 8
CML see chronic lymphatic leukaemia
CMPO 432
CNS see central nervous system
codine 163, 171
CODOX-M regimen 396
cognitive behavioural therapy 167
cognitive impairment 51
controversies 325
coverage 51
inception cohort 26
prognostic factors 25–6
time-zero 26
COL1A1-PDGFB 759
colorectal cancer 123
COLD 129–149
colony-forming cells 110
colony-stimulating factors 129, 149
colorectal cancer 308–26
biomarkers 51, 316
clinical trials 325
controversies 325
diagnostic work-up 313–15, 313
follow-up and surveillance 324
hereditary 309–10
imaging 76–7, 77
incidence and aetiology 309–10, 309
older patients 141
palliative care 325
pathology and molecular biology 313, 313
prevention 310–11
prognostic factors 316–17, 317
quality of life 324
research priorities 326
risk factors 309
screening 309, 311–12
staging 314, 316
survivorship 325
\textbf{treatment}
corticosteroids 66
contrast-enhanced CT 63
constipation 159–61
cushing disease/syndrome 160
curative therapy 63
CUP 65
CTCAE 57
CT
cryotherapy
cryoablation

crizzotinib 217
cumulative risk 5
CUP see cancer of unknown primary
curative therapy
radiotherapy 117–18
supportive care 155–67
surgery 101–3
see also individual cancers
Cushing disease/syndrome see hypercortisolism
cyclin D 545
cyclophosphamide
CHOP regimen 128, 412, 739
Hodgkin lymphoma 396
myeloma 419
non-Hodgkin lymphoma 411
salivary gland tumours 584
CYP3A4 induction/inhibition 143
cytarabine
CNS tumours 721
Hodgkin lymphoma 396
cytokeratins 601
cytokines
melanoma 701–2
renal cell carcinoma 365
side effects 153
cytopathology 91–3, 91, 92
methods and specimen types 92–3, 93
screening, reporting and quality control 92
specimen collection 92
cytotoxic chemotherapy 124
colorectal cancer 321–3, 322–3
see also individual drugs
D
dabrafenib 698
dacarbazine
ABVD regimen 136, 396
Hodgkin lymphoma 396
DAHANCA 5 study 113
DART initiative 55
dasatinib
CML 443
data
anonymization 58–9
collection protocols 56
confidentiality 58
disclosure 58
infrastructure 55–6
interoperability 57, 57
patient- and caregiver-managed
59
see also informatics
databases 56–7
centralized 55–6
federated 56
non-relational (NoSQL) 56–7
Data governance Committee 59
data warehouses 57
Davinci system 107
decision support 60, 60
dehydration 156
delirium 179
demeclocycline 150
denileukin diftox 412
Denoix, Pierre 34
depression 156
psychosocial care 166
treatment see antidepressants
descriptive epidemiology 3–4, 4
desmin 601
desmoid tumours 757, 765
determinant of disease 3, 4
desmethylasone 176, 178
Hodgkin lymphoma 396
myeloma 419, 421
DHAP regimen 396
diagnosis 104
see also individual cancers
diagnostic markers see biomarkers
diarhoea 157–9
assessment 158
exudative 157
nutritional treatment 158, 158
osmotic 157
palliative care 176–7
patient education 159
treatment 157–9, 159
diclofenac 170
DICOM standard 59
diet 156
as cancer risk factor 8–9
survivors 187
see also nutritional treatment
differential thyroid cancer 631–5
controversies 634–5
treatment 632–4
principles 631, 631, 632
radioactive iodine 633–4, 634
radiotherapy 632–3
surgery 632
systemic therapy 633
TSH suppression 633, 635
diffuse large B-cell lymphoma
paediatric 773
pathology and natural history 400
treatment 409
diltiazem, drug interactions 143
dimethyldimine 178
diphenhydramine 176
disclosure of data 58
disease extent 28, 29
disease-free survival 40
disease type 28
distant control 40
distant metastasis-free survival 40
distribution of disease 3, 4
DNA
damage/repair 109–10
sequencing 95
structure 110
doctaxel
head and neck cancers 509
lung cancer 214, 215
oral cancers 538
ovarian cancer 488
prostate cancer 339
dolasetron 153
domeridine 138, 176
dose interval 128–9
dose-response curves in radiotherapy 110–11, 111
dose-volume histogram 119
doxorubicin
bone tumours 750, 751
CHOP regimen 128, 412, 739
Hodgkin lymphoma 396
salivary gland tumours 584
uterine cancer 475
dronabinol 156
drug dose 128–9
drug-drug interactions 143, 143
drug toxicity 41–2, 130
ductal carcinoma of breast 223
local therapy 230
duloxetine 166
duodenal neuroendocrine tumours 660
dysgerminomas 482
dysphagia 197
dysplasia 92
dyspnoea 179
E
EBER 601
echocardiography 130
effect size 40–1
effusions, malignant 151–2
EGFR 109, 117, 545, 579
EGFR inhibitors 216–17, 217
colorectal cancer 323
oral cancers 538
EGR gene mutation 216, 316
electrolyte depletion 156
electrolyte replacement therapy 159
electronic medical records 54
elotuzumab 421
EMA 89, 600
emergencies 145–54
adrenal insufficiency 150
brain metastases 146
cytokine use 153
hypercalcaemia 149
malignant effusions 151–2
neutropenic fever 147–9
pain-related 173
refractory nausea and vomiting 152–3
SIADH 149–50
emergencies (continued)  
spinal cord compression 146–7  
superior vena cava syndrome 145–6, 146  
thrombosis and hypercoagulability 150–1  
transfusion use 153  
tumour lysis syndrome 150  
end of life care 182–3  
see also palliative care  
endobronchial ultrasound 208  
edendobronchial ultrasound-guided fine needle aspiration (EBUS-FNA) 93, 208  
edocrine disorders, and fatigue 156  
edendodermal sinus tumours 482  
edometrial cancer  
images 79–80  
older patients 141  
energy conservation 157  
enteropathy-associated T-cell lymphoma  
pathology and natural history 404  
treatment 413  
environment-related prognostic factors 32, 32  
enzalutamide 339  
ediology 3–11  
analytical 3, 4–5  
descriptive 3–4, 4  
experimental 5  
global burden 5–7, 6  
prevention 10–11  
risk factors 7–10, 7  
edipetal growth factor receptor see EGFR  
edipalinalrinical leaky neurelysis 172  
edipubic  
edoccasion cancer 290  
salivary gland tumours 584  
ediptelial growth factor receptor see EGFR  
edipetal markers 89  
EPOCH regimen 396  
Epstein-Barr virus 8  
ERG 89  
erlotinib  
lung cancer 213, 215, 217  
edrihydromycin 432  
edrihybroplasia of Queyrat 385  
escalotram 166  
ESHAP regimen 396  
esthesio-neuroblastoma (ENB) 588  
ethics  
end of life care 182  
palliative care 181  
etoposide  
CUP 795  
germ cell tumours 489  
Hodgkin lymphoma 396  
lung cancer 218  
testicular cancer 381  
European Organization for Research and Treatment of Cancer (EORTC) 169  
European Union, Biobanking and Biomolecular Research Infrastructure 56  
ethanasia 182  
etovolimus  
edonodocrine tumours 667, 668, 669  
edernal cell carcinoma 365  
EWSR1–AF7 759  
EWSR1–CREB1 759  
EWSR1–DDIT3 759  
exercise 157, 187  
experimental epidemiology 5  
ion exposure misclassification 5  
external beam radiation  
eyelid cancers 742  
ocular adnexal lymphoma 739  
retinoblastoma 735  
external review of CPGs 21–2  
edereadily plasmacytoma 418  
edonal marginal zone lymphoma,  
MALt type  
pathology and natural history 401  
treatment 410  
edonal NK/T-cell lymphoma, nasal type  
pathology and natural history 405  
treatment 413  
exudative diarrhea 157  
eyelid cancers, 740–3, 740  
diagnostic work-up 741  
incidence and aetiology 740  
pathology 740, 740–1  
post-treatment assessment 742–3  
presentation 741  
prognostic factors 742  
staging 741, 742  
treatment 742  
principles 741  
eye tumours see specific types  
F  
faecal impaction 177  
see also constipation  
fallopian tube cancer 491–4  
diagnostic work-up 492, 492  
incidence and aetiology 491  
presentation 492  
prognostic factors 493  
staging 492, 492  
treatment 493–4  
principles 493, 493  
radiotherapy 493  
surgery 493  
systemic therapy 494  
see also ovarian cancer  
familial adenomatous polyposis 310  
familial cancer syndromes 90  
famotidine 178  
fatigue see cancer fatigue  
FDG-PET 54, 65  
Hodgkin lymphoma 398  
response assessment 46, 50  
site-specific  
CNS tumours 66  
colorectal cancer 314  
febrile neutropenia 142  
federated databases 56  
fentanyl 163, 171  
18F-fluorothyroxine-L-tyrosine-PET 66  
18F-fluorothyridine-PET 66, 67  
field intervention trials 3  
FiGO classification  
cervical cancer 79, 458, 459  
fallopian tube cancer 492, 492  
ovarian cancer 483, 484  
uterine cancer 471  
vulvar cancer 497  
fine needle aspiration (FNA) 92–3, 93, 104  
edendobronchial ultrasound-guided 93  
thyroid cancers 68, 92, 629  
Fite stain 88  
floor of mouth 70  
imaging 535  
FRα-TD mutation 433  
fluconazole, drug interactions 143  
fudarabine  
CLL 447  
non-Hodgkin lymphoma 411  
fluorodeoxyglucose see FDG  
fluorouracil (5-fluorouracil)  
anal cancer 330  
head and neck cancers 509  
oesophageal cancer 289, 290  
penile cancer 389  
PIAF regimen 258  
salivary gland tumours 584  
fluoxetine 156, 166  
FNA see needle aspiration  
FOLFR I 795  
FOLFOX 795  
folicular lymphoma  
pathology and natural history 400  
prognostic factors 407  
treatment 409  
Fontana-Masson stain 88  
Formatted Anthology Synoptic Tick (FAST) sheet 55  
sosamprenavir, drug interactions 143  
Framework Convention on Tobacco Control (FCTC) 11  
French-American-British (FAB) classification 431  
FUS–DD173 759  
G  
G-8 geriatric screening tool 140  
gabapentin 164  
Gardner syndrome 310  
gastric cancer 297–307  
biomarkers 300  
clinical trials 305–6  
controversies 304–5  
diagnostic work-up 300  
imaging 74–5  
incidence and aetiology 298  
natural history 299, 299–300  
pathology 298, 299  
prognostic factors 301  
risk factors 8  
screening 298  
staging 300, 301  
treatment 302–4  
principles 301–2, 301–2  
radiotherapy 303–4  
surgery 302–3  
gastric neuroendocrine tumours 659  
systemic therapy 668–9, 669  
gastrointestinal stromal tumours 757  
imaging 77–8, 78  
standardized response criteria 48  
GCDFP-15 601  
GDP regimen 396  
gefitinib 125  
lung cancer 213, 215, 217  
gemcitabine  
biliary cancers 268  
bladder cancer 350  
CUP 795  
Hodgkin lymphoma 396  
lung cancer 214  
nasopharyngeal cancer 520  
gentuzamab ozogamicin 436  
Gene Expression Omnibus 56  
gene therapy 126  
genetic susceptibility 10  
genome-wide association study 10  
genomics 53  
geriatric assessment scales 140  
germ cell tumours  
biomarkers 51  
CNS 708  
ovary 481, 482, 488, 489  
germinoma 708  
gigantism 613  
gingiva 70
Index

830

surgical pathology (continued)
  intraoperative consultation 85–6, 85, 86
  processing and mounting 87
  reporting 90, 97
  specimen handling 83–5, 84
  surveillance
    cancer survivors 185–6
    postoperative 106
  surgical aspects 103–4
  survivorship care
    184–93
  definitions of survivorship 184–5
  elements of 185–8, 185
    persistent/fate side effects 186–7
    prevention and health promotion 187–8
  surveillance 185–6
  healthcare delivery 188–9, 188, 189
  low and middle income countries 190
  patient and family education 192
  professional education/training 191–2
  research priorities 190–1
  Survivorship Care Plan (SCP) 189, 189
  sympathetic nerve block 172
  synaptophysin 89, 601
  syndrome of inappropriate antidiuretic hormone secretion see SIADH
  synovial sarcoma 758
  systematic reviews 15

  Systematized Nomenclature of Medicine see SNOMED

  systemic therapy 126
  adjuvant therapy 102–3, 126, 127
  biliary cancers 268
  bladder cancer 349–50
  bone tumours 750–1
  breast cancer 233–5, 233–5
  cancer gene therapy 126
  cervical cancer 464
  chemotherapy 124–33
    cytotoxic 124
    hormone therapy 124–5
    immune therapy 126
    molecularly targeted 125–6, 126
    older patients 140, 142, 142
    pregnancy 135
  CNS tumours 709, 716–17, 719, 720, 721, 721
  colorectal cancer 321–3, 322–3
  cost-effectiveness 132
  drugs, dosage and dose intervals 128–9
  duration of 129
  fallopian tube cancer 494
  head and neck cancers 509
  unknown primary 606
  liver cancer 258, 258
  lung cancer 213–19
  lymphoma 774
  metastatic/disseminated cancer 127–8
  monitoring 130–1
  nasopharyngeal cancer 520
  neoadjuvant (preoperative) therapy 103, 126, 127
  neuroendocrine tumours 665–9, 666–9
  oesophageal cancer
    adenocarcinoma 294
    squamous cell carcinoma 289–90
  oral cancers 537, 537–8
  pancreatic cancer 277
  patient co-morbidities 131, 131–2
  penile cancer 389, 389
  pregnancy 136
  prostate cancer 338–40
  refractory/relapsing cancer 129–30
  renal cell carcinoma 363–6, 364–6
  route of administration 131
  salivary gland tumours 584, 584
  sinonasal tumours 595, 595
  skin cancer
    melanoma 701–2
    NMSC 684, 685
  soft tissue tumours 765
  thyroid cancers
    anaplastic 637
    differential thyroid cancer 633
  medullary 638
  toxicity 41–2, 130
  uterine cancer 475, 475
  vulval cancer 500
  see also individual drugs

T
  tamoxifen 136
  tapentadol 163
  targeted therapy 125–6, 125
  AML 436
  clinical trials 476
  lung cancer 316–17, 317
  renal cell carcinoma 364–5, 364, 365
  salivary gland tumours 584
  soft tissue tumours 765
  uterine cancer 477
  taxanes
    patient co-morbidities 131–2
    see also individual drugs
  taxonomy in prognostic factor studies 23, 28–9
  T-cell lymphoma
    pathology and presentation 403–5
    treatment 412–13
  99mTc-glucolactone 66
  99mTc-sestamibi 66
  99mTc-dodecyselenomycin 66
  technical errors 86
  telesurgery 107
  telithromycin, drug interactions 403–5
  telesurgery 107
  follow-up 381, 381
  imaging 81
  incidence and aetiology 368, 369
  natural history 370, 370
  pathology 369, 369, 370
  presentation 370
  prognostic factors 372, 373
  screening 369
  staging 372–3, 372–3
  treatment 375–81
    CSIIA 376, 377, 378, 378
    CSIII 377, 379
    principles 373–4, 375
    relapsed/refractory tumours 380, 380, 381
  TIN and CSI 375, 375–7
  testicular intratubular neoplasia (TIN) 370
  thalidomide
    myeloma 419, 420
    The Cancer Imaging Archive (TCIA) 56
  therapeutic ratio 109
  thoracic cancers
    imaging 72–3, 73, 74
    see also specific sites
  thomboembolopatia 153
  thrombosis 150–1
  thyroglobulin 51, 601
  thyroid cancers 626–40
    anaplastic 635–7, 635–7
    biomarkers 51, 629
    clinical trials 639
    diagnostic work-up 628–9, 629
    differential thyroid cancer 631–5
    controversies 634–5
    treatment 631, 631–4
  FNA 68, 93, 629
  group classification 629
  imaging 67–8, 68, 69
  incidence and aetiology 626–7
  medullary 637–8, 637, 638
  pathology and natural history 627–8
  presentation 628
  prognostic factors 630, 630
  research priorities 639
  screening 627
  staging 629, 630
  thyroidecction 634–5
  thyroid stimulating hormone 67, 68
  thyrotroph-secreting tumours 611
  presentation 613
  treatment 622–3
  time to progression 43
  time-zero 26
  tirapazamine 113
  tissue fixation 83–5, 84
  TNM staging 29, 31, 105
  additional descriptors 37–8
  anatomical regions and sites 36
  clinical classification 36–7, 36
  general rules 35–6
  histopathological grading 37
  history 34–5
  isolated tumour cells 37
  operational descriptors 38
  residual tumour 38
  sentinel lymph nodes 37
  stage group 38
  see also individual cancers
  tobacco
    as cancer risk factor 7
    use by cancer survivors 188
  tolavaptan 150
  tongue
    imaging 70
  tumours of 535
  toxotumorab buxetan, non-Hodgkin lymphoma 409
  TPS 545
  traditional prognostic factors 27
  tramadol 163
  transarterial chemoembolization (TACE)
    with drug-eluting beads 257
  liver cancer 256–7, 256, 257
  neuroendocrine tumours 671
  transbrachial needle aspiration (TBNA) 208
  transrescriptomics 53
  translational bioinformatics 55–6, 58
  treatment algorithms 29
  treatment outcome see outcome reporting
  treatment scenario 24
  tricyclic antidepressants 164, 166
  TTF-1 601
  tumour behaviour 100
  tumour blood markers 31
tumour lysis syndrome 150, 773
tumour markers see biomarkers
tumour microenvironment 112–13
tumour profile 29, 30–1, 30
tumour-related prognostic factors 30–1, 30
tumour spread see metastases
tyrosinase 89
tyrosine kinase inhibitors
  CML 442–4, 443
  resistance 444
U
  UICC 29–30, 30, 34, 35
  see also TNM system
ultrasound 63, 64–5
  lung cancer 208
  response assessment 43
  thyroid cancers 68, 68
unfractionated heparins 151
Union for International Cancer Control
  see UICC
urine cytology 93
urogenital cancers see specific sites
urothelial cancers see bladder cancer
USA
  Health Insurance Portability and Accountability Act (HIPAA) 59
  National Cancer Informatics Program 56
  National Cancer Institute 4
  National Center for Biomedical Oncology 57
uterine cancer 467–78
  controversies 477
  diagnostic work-up 470
  incidence and aetiology 468–9
  pathology 469
  presentation and natural history 469–70, 470
  prognostic risk factors 470–1, 471
  research priorities 477
  screening 469
  staging 471
  treatment 473–5, 477
  hormonal therapy 475, 477
  principles 471–3, 472–3
  radiotherapy 474–5
  surgery 473
  systemic therapy 475, 475
  targeted therapy 477
uveal melanoma 693, 727–32, 727
  clinical trials 743
  controversies 732
  diagnostic work-up 728
  incidence and aetiology 727
  pathology 728
  post-treatment assessment 732
  presentation 728, 728
  prognostic factors 730, 730
  staging 729–30
  treatment 731
  principles 730, 731
V
  validity 43
  van Gleson stain 88
  vascular endothelial growth factor see VEGF
  vascular markers 89
  VEGF 545, 579
  VEGFR 757
  VEGR 757
  venlafaxine 166
  venous invasion 38
  venous thromboembolism 151
  verapamil, drug interactions 143
  Verner Morrison syndrome 666
  VES-13 140
  video-assisted thoracic surgery 208
  vimentin 601
  vinblastine
    ABVD regimen 136, 396
    CNS tumours 717
    Hodgkin lymphoma 396
  vincristine
    CHOP regimen 128, 412, 739
    CNS tumours 717, 721
    Hodgkin lymphoma 396
    patient co-morbidities 131–2
  vinflunine 350
  vinorelbine
    lung cancer 214
    nasopharyngeal cancer 520
  salivary gland tumours 584
  VIPoma 666
  virilizing syndromes see hyperandrogenism
  visual assessment 44
vitamin D deficiency 686–7
volumetric-modulated radiotherapy 120, 120
von Kossa calcium stain 88
voriconazole, drug interactions 143
vorinostat 412
vulval cancer 495–502
  clinical trials 501
  controversies 501
  diagnostic work-up 497
  HPV-related 496
  incidence and aetiology 496, 496
  natural history and presentation 496, 496–7
  pathology 496
  prognostic factors 497–8, 498
  research priorities 502
  screening 496
  staging 497
  treatment 499–500
  principles 498, 498–9
  radiotherapy 500, 500
  surgery 499, 499, 500
  systemic therapy 500
W
  weight loss 156
  Whipple triad 666
  Wilms tumour 785–6, 785, 786
  imaging 79
  women
    breast cancer 221–40
    cervical cancer 449–66
    fallopian tube cancer 491–4
    ovarian cancer 479–91
    uterine cancer 467–78
    vulval cancer 495–502
  World Health Organization (WHO) 23
    Classification of Tumors 29, 39
    International Classification of Diseases for Oncology (ICD-O) 39
    three-step analgesic ladder 170
    World Wide Web (www) 57
X-rays in response assessment 43
Ziehl-Neelsen stain 88
Zollinger-Ellison syndrome 666